USANA Health Sciences (NYSE:USNA – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50), FiscalAI reports. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.40%. The company had revenue of $223.27 million during the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences updated its FY 2026 guidance to 0.760-0.760 EPS.
USANA Health Sciences Stock Performance
Shares of NYSE:USNA opened at $15.00 on Thursday. USANA Health Sciences has a 1 year low of $14.48 and a 1 year high of $32.32. The stock has a market capitalization of $276.91 million, a P/E ratio of -12.39, a PEG ratio of 0.90 and a beta of 0.73. The stock has a 50-day simple moving average of $20.55 and a 200-day simple moving average of $19.74.
Analyst Upgrades and Downgrades
Several research firms have weighed in on USNA. Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, USANA Health Sciences has a consensus rating of “Reduce”.
Insider Activity at USANA Health Sciences
In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the sale, the director owned 4,230 shares in the company, valued at approximately $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brent Neidig sold 5,002 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 13,869 shares of company stock valued at $261,441. Corporate insiders own 0.82% of the company’s stock.
Institutional Investors Weigh In On USANA Health Sciences
Hedge funds and other institutional investors have recently made changes to their positions in the stock. National Bank of Canada FI lifted its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after buying an additional 1,901 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in USANA Health Sciences by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after buying an additional 1,327 shares during the last quarter. Parallel Advisors LLC grew its position in shares of USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after acquiring an additional 3,589 shares during the period. Finally, Quantbot Technologies LP raised its holdings in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after purchasing an additional 646 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.
About USANA Health Sciences
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
See Also
- Five stocks we like better than USANA Health Sciences
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
